"Focus": The Word That Kills Platform Companies

Let me say something that might surprise you, given the title of this article: focus is essential.

A preclinical biotech with eighteen months of runway and three programmes competing for the same bench time needs to prioritise ruthlessly. A Series A company with £8M in the bank cannot resource five clinical candidates simultaneously. Capital discipline, milestone clarity, the operational rigour of concentrating resources on the work that matters most right now: these are not optional. They are how biotech companies survive.

Every advisor, every VC, every board member who has ever told a founder to focus was, in most cases, giving sound operational advice. I've given it myself. I've lived it. I'm living it now.

So why am I writing an article arguing that "focus" kills companies?

Because the biotech industry has a language problem. It uses one word to describe two entirely different actions. The first is sequencing: deciding which programmes to resource now and which to defer, while preserving the ability to return to them. The second is amputation: permanently eliminating programmes, dismantling platform infrastructure, destroying optionality the company will never recover.

Sequencing is discipline. Amputation is surrender.

The word "focus" makes them sound identical. They are not. And I've built two platform strategies that were destroyed because people at the board table couldn't tell the difference.

The consensus on focus exists for good reasons. Platform companies raised the majority of biotech venture capital between 2019 and 2021. Investors bought the thesis: platforms offer multiple shots on goal, strategic optionality, and a hedge against the reality that roughly 87% of clinical assets never reach market approval. Then the market turned. Capital became scarce. Some of those platform companies were genuinely over-extended: too many programmes, too little resource, no clear prioritisation. When their boards said "focus," they were right.

But something else happened alongside that legitimate correction. The word migrated. It stopped being operational advice about resource allocation and became strategic doctrine about programme elimination. Boards that couldn't evaluate platform complexity started using "focus" to justify removing what they couldn't understand. Shareholders who wanted simpler stories started using "focus" to justify narrowing the value they'd funded. Operators who preferred managing one programme to managing three started using "focus" to justify amputating the optionality their investors had paid for.

The word remained respectable. The action it described became destructive.

This is the fourth article in a series on the decisions that kill biotechs. The first three examined board composition, the CEO-Chairman relationship, and what happens when the scientific voice is silenced. This article is about the specific strategic decision that governance failures most often produce. About how a word that describes genuine operational discipline got hijacked to justify strategic destruction. And about the medicines that died because nobody in the boardroom asked which version of "focus" was being proposed.

I've built two platform strategies in my career. Both were destroyed by the same word.

Different companies. Different science. Different therapeutic areas. Different people around the table. Different years. But when I look back at the conversations that preceded the decisions, at the precise moment each platform was dismantled, the same word appears.

Each platform shared the same architecture: a core scientific foundation that could generate multiple programmes addressing distinct patient populations. Not theoretical diversification. Real optionality built on real biology. In both cases, I assembled the team, built the board, secured the regulatory pathway, raised the capital, and developed a detailed strategy to capture the full platform value. Meticulous work, done over years, designed to give each company the best chance of surviving the brutal mathematics of drug development.

In both cases, the platform was amputated by people who called it sequencing.

I've seen "focus" used to disguise two entirely different failures of governance. The first is ownership arithmetic. I've built a platform where controlling shareholders rejected transformative investment because funding the full strategy meant dilution. They would own a smaller percentage of a larger, more valuable company. They preferred to own a larger percentage of a narrower one. A bigger slice of a smaller pie. They called it "focus." What they meant was: we'd rather own more of less than build something transformational.

My Chairman and I understood what had happened. The strategic decision had nothing to do with strategy. The shareholders' time horizon didn't match the opportunity. They wanted control more than they wanted value creation. We both walked away. On principle. Because a company whose controlling shareholders would sacrifice transformative value to avoid dilution would keep making the same choice until there was nothing left to dilute.

That company was eventually sold for effectively no cash to shareholders. The platform that could have captured an entire treatment pathway was never built.

The second failure is comprehension. A platform where the science had genuine potential across multiple diseases, built on years of academic work, funded by a Series A specifically intended to develop the platform's full range. After a governance crisis removed the CEO, the new leadership's first strategic act was to abandon every programme except one. They called it "focus." What they meant was: we don't understand this, so we want less of it.

As I described in the previous article, the scientific founder who understood the biology was silenced. Demoted. Excluded from the research programme he had created. The operators who replaced him looked at multiple programmes and saw complexity. They saw complexity and saw cost. They saw cost and reached for the word that justified elimination. What they didn't see, because they lacked the scientific fluency to see it, was that the platform was the value. The multiple programmes weren't overhead. They were the hedge. They were the reason the investors had written the cheque.

The single compound they chose to develop failed. The company went bankrupt. The platform that could have provided alternatives had already been dismantled. The patients who needed those medicines will never receive them.

Two platforms. Two mechanisms of destruction. One word.

Neither of these was a sequencing decision. Nobody said "let's defer these programmes and return to them when we have the capital." They said "we're cutting everything except the lead." That's amputation. And in both cases, the amputation killed the patient along with the limb.

The difference between sequencing and amputation is not semantic. It is the difference between a company that can survive its first clinical failure and one that dies alongside it.

Platforms create hedges. If the lead compound fails, the platform gives you somewhere to go. Removing the platform doesn't de-risk the company. It concentrates all risk into a single outcome. Yet boards routinely treat optionality as complexity, because optionality is harder to model than a single discounted cash flow.

This is not a theoretical concern. A retrospective analysis of platform companies from their Series A rounds found that platform companies showed higher rates of continued development after lead asset failure compared to their single-asset peers. The platform was the survival mechanism. In an industry where roughly 13% of Phase 1 assets reach approval, the ability to absorb a failure and continue isn't a narrative convenience. It's the difference between a company that lives and one that doesn't.

I've known operators who couldn't see this. They looked at multiple programmes and saw overhead. They looked at a platform and saw complexity they couldn't manage. Complexity they didn't understand wasn't complexity that didn't exist. It was value they were incapable of recognising, dressed up in a spreadsheet that made elimination look like efficiency.

The question isn't "platform or single-asset?" in the abstract. It's "are we sequencing or amputating?" Sequencing preserves optionality. Amputation destroys it. The first is a resource allocation decision that a competent board can make. The second is a scientific decision that requires scientific judgment. Boards that treat amputation as a resource allocation decision are making a category error. And they're using the word "focus" to hide it.

I tell these stories not to relitigate decisions that can't be undone, but because the pattern continues. Right now, in boardrooms across the UK biotech sector, someone is using the word "focus" to justify an amputation that will destroy optionality their company needs to survive. I also tell them because I want to be clear about what genuine operational focus looks like when it's done with strategic integrity.

At Santero, we're navigating this tension in real time. Our RSH enzyme inhibitors target a mechanism conserved across all bacteria: Gram-positive and Gram-negative, acute and chronic infections. In chronic respiratory disease alone, a platform targeting the bacterial mechanisms behind treatment failure has potential applications across bronchiectasis, chronic rhinosinusitis, chronic wounds, and prosthetic joint infections. That is not theoretical diversification. It is multiple billion-dollar markets accessible from the same scientific foundation. Genuine platform biology, not a narrative convenience.

We've chosen to sequence development deliberately, establishing proof-of-concept in our lead chronic disease programme before expanding. But the platform architecture remains intact. Every programme we defer is a programme we can return to. Nothing has been dismantled. Nothing has been surrendered. That's the critical distinction: a conscious sequencing decision made by people who understand both the science and the strategy, with the full platform preserved for when the company is ready to expand.

At AMPLY Discovery, where I serve as Chairman, the platform is the entire value proposition. The AI/ML drug discovery engine targets multiple oncology indications. Narrowing to a single programme would destroy the company's thesis. When investors ask about "focus," we explain why the breadth is the point, and we do it in language that respects their need for clarity without sacrificing the scientific argument.

The companies I lost made the opposite choice. They didn't sequence. They amputated. And once you amputate, there's no going back when the lead programme fails.

If you're a CEO navigating this decision, or a founder trying to preserve optionality against board pressure, the sequencing-versus-amputation distinction gives you a practical framework. But you need structural protections to make it stick.

Make the optionality argument before you need it. The worst time to explain platform value is when you're running out of money and investors are demanding a simpler story. Educate your board on why the platform matters when you're raising, not when you're struggling. If they understand the scientific rationale for breadth before pressure hits, they're less likely to reach for "focus" when it does.

Frame platforms in investor language. Investors understand risk-adjusted net present value. Frame the platform as a portfolio of probability-weighted assets. Show them how the expected value calculation changes when you account for lead asset failure. Make them see that narrowing increases risk rather than reducing it.

Introduce the vocabulary. When someone at your board table says "we need to focus," ask: do you mean sequence or amputate? That single question reframes the conversation. Sequencing is reversible. Amputation is not. Make the board own which one they're proposing.

Ensure scientific fluency at the board level. Directors who understand the underlying biology can evaluate whether the platform has genuine scientific value or is a narrative convenience. Those who can't will default to financial simplification. This is why I've argued throughout this series that scientific fluency on the board is non-negotiable.

Establish decision rights that require scientific sign-off on pipeline changes. Programme elimination is a scientific decision. If your governance allows operators to make it unilaterally, your platform is already at risk.

Behind every abandoned platform is a board that used the word "focus" to describe something they didn't understand. Behind every abandoned platform is a medicine that will never reach patients who need it.

I know this because I built two of those platforms. I watched both get dismantled. I watched patient populations lose potential therapies they will never know existed. Those aren't abstract strategic consequences. Those are real costs borne by real people who will never know that a boardroom conversation about "focus" determined their treatment options.

The largest unaddressed opportunities in drug development are not in the spaces where everyone is competing. They are in the spaces where governance failures and intellectual surrender have prevented the right companies from being built. Those opportunities exist right now, in diseases where the unmet need is greatest, waiting for companies with the scientific fluency and the governance discipline to pursue them.

The biotech industry is right that focus matters. It is wrong about what the word means.

Sequencing is how disciplined companies survive. Amputation is how promising companies die. The next time someone at your board table says "we need to focus," ask them which one they're proposing.

The answer will tell you whether your platform, and the medicines it could produce, will survive.

This is the fourth article in a six-part series on biotech governance. Next: What gets lost when founders are pushed out, and what happens when one gets a second chance.

I write Beards on Biotech because I've built things that governance destroyed. If the word "focus" has ever been used in your boardroom to justify a decision that destroyed optionality, I'd like to hear the story.